AzTrials
AzTrials

Alzheimer DiseaseNCT05218018

Triglyceride Effects on Blood Flow in the Human Brain

A study testing Lipid drink in people with Alzheimer Disease, run by University of Washington at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The 'Western diet' characterized by high fat feeding (HFF) is a risk factor for Alzheimer's disease (AD); however, little is known about mechanisms. Paradoxically, individuals who carry the AD risk gene APOE E4 cognitively improve after HFF and show different metabolic responses to fat intake. Read more about this study

Who is it for?
Ages 55 years and olderHealthy volunteers can take part
Conditions the study is for
Alzheimer Disease
What is being tested?
Lipid drink
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited States
Study dates
1 Mar 2020to 13 Jan 2022
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Previously completed the Meal and Memory study
  • Age 55 and older
  • Able to read and understand English
  • Able to give informed consent
  • Able to undergo MRI and ingest dairy products

Who cannot join

  • Did not screen in the Meal and Memory study
  • Allergic to or not able to ingest study ingredient (dairy)
  • Metal in body or otherwise unable to lay still for an MRI

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Washington Medical Center

    Seattle, Washington, 98104

Other trials in United States

About this study

The 'Western diet' characterized by high fat feeding (HFF) is a risk factor for Alzheimer's disease (AD); however, little is known about mechanisms. Paradoxically, individuals who carry the AD risk gene APOE E4 cognitively improve after HFF and show different metabolic responses to fat intake. These responses include a more pronounced drop in systolic blood pressure and a decrease in cerebrospinal fluid glucose and lactate levels. This proposal will further examine the brain metabolic response to HFF using non-invasive imaging. Cerebral blood flow (CBF) as assessed by functional MRI is increasingly utilized to investigate brain function, given that CBF is tightly coupled to brain metabolism. Acute changes in CBF have been described in response to carbohydrate ingestion in regions important for learning and memory; however, no one has yet assessed CBF response to lipid. Here investigators propose to characterize CBF changes to a high fat drink in older adults. This study will include a time course assessment as well as analyses of global and regional change in CBF. These data would serve as feasibility pilot data for an R01 application which would include cognitive and peripheral metabolic data. These types of studies will provide a clearer picture of acute brain metabolic response to HFF in older adults, including the effects of APOE.

Read the detailed description

Overview: High fat feeding (HFF) is a risk factor for AD, but this risk factor is modulated by APOE genotype. Acute meal studies including lipid tolerance tests are increasingly being used to understand mechanisms by which diet affects disease processes. Investigators have consistently shown that E4 carriers respond differently to HFF in acute meal challenges; this study will further explore this phenomenon in older adults by assessing cerebral blood flow (CBF), given its tight coupling to brain metabolism. Here investigators propose to use arterial spin labeling (ASL) MRI as this non-invasive imaging technique can detect small changes in global and regional CBF, and acute ∆CBF in response to nutrients have been demonstrated in humans. With this project investigators will determine the most optimal time point for detecting post-lipid ∆CBF, as well as determine which regions of the brain respond to HFF. To our knowledge, this study would be the first to assess ∆CBF using ASL; these pilot data will then assist with future grant applications in this area.

Specific aims: 1. To determine which time point (1, 2, or 3 hours) produces the most robust ∆CBF after ingestion of a lipid drink in 30 older adults. 2. To determine which regions of the brain respond to HFF.

Methods: Participants: All study procedures will be submitted to the UW Institutional Review Board for approval. Investigators maintain a database of ~40-50 participants from the Meal and Memory study who have already agreed to be contacted for future studies; investigators will recruit 30 participants. Inclusion criteria are as follows: age 55 and older, able to read and understand English, able to give informed consent, and able to undergo MRI and ingest dairy products. All interested participants will undergo telephone screening to ensure they meet inclusion criteria. If they meet criteria, they will be mailed a reminder letter which will instruct them to fast the night before. They will also receive a copy of the consent form to look over, and a medical history form to fill out, including an MRI safety checklist which asks them about prior surgeries and whether they have any metal in their body.

Study visit: Participants will fast the night prior (12 hours prior to the visit time); medications and water are ok. They will arrive at the South Lake Union facility between 8 and 10 am. They will undergo informed consent in a quiet room from the study team (either the PI or the study coordinator) and given plenty of opportunities to ask questions. If they choose not to enroll in the study, they will be discharged from the unit and parking or transportation will be reimbursed. As a part of the consent process, investigators will ask participants to give optional written permission on the consent form to release their APOE genotype from the Meal and Memory Study, or other Alzheimer's research study they may have participated in. Investigators will not disclose this genotype to anyone outside the study team including the participant.

If the participant enrolls in the study and signs a consent form and a research HIPAA form, then the protocol will begin. Vitals will be assessed by the study team, including blood pressure, heart rate, and height/weight and BMI calculation. Participant will be escorted to the MRI machine by the study team, who will also bring down the lipid drink in a cooler. An MRI technician experienced with research MRI procedures will conduct the MRI portion. First a 15 minute ASL protocol will be run, then the participant will be given the heavy cream (100 mls, or just under half a cup, which contains 370 calories, 40.4 grams of total fat, 23.6 grams of saturated fat). Investigators will encourage the participant to drink the product over 5 minutes. Participants will then undergo 3 more 15-minute scans at 1, 2, and 3 hours post drink. It is possible that some of the acquisition times can be slightly longer than 15 minutes. After the last MRI image acquisition, lunch will be offered (up to $15 at a nearby restaurant), participants will receive a gift card, and parking or transportation will be reimbursed, and be discharged.

Alternative site: UWMC will run the last 2-4 participants to ensure the MRI protocols and sequences are similar, in order to prepare for Lipid MRI 2.0. Participants will check in at the DISC lab and vitals will be done there including height and weight for BMI calculation.

MRI protocol: The MRI is non-invasive with no need for contrast. In addition, investigators will not be performing a clinical MRI and these findings cannot be used to diagnose any brain condition. For the ASL protocol, we will use pseudo-continuous arterial spin labeling to measure CBF in ml/100g/min as a marker of perfusion for improved signal quality. In this approach, magnetically labeled arterial blood water serves as the endogenous contrast. Investigators will use a sequence (5.5 minutes) with long label duration = 1.8 s, long post-labeling delay = 2 s, with labeling offset = 25-30 mm, slices = 20, spatial resolution = 3.5×3.5×5 mm3, field of view = 240×240×100 mm3, SENSE-factor = 2, TR/TE= 5000/18 ms. Investigators will apply dual adiabatic background suppression pulses to minimize gray and white matter tissue contamination at TI = 2.05 and 3.25 s. Finally, investigators will acquire an equilibrium magnetization scan (M0, 1 minute), identical to the above scan, but with TR = 10,000 ms and no labeling or background suppression. For the last 8 subjects investigators will add a T2 multi-echo sequence (approximately 10 minutes) to detect changes in the appearance of the hypothalamus from before to after lipid ingestion.

Analysis: Analysis will be done under the supervision of Dr. Rane and the UW Diagnostic Imaging Sciences Center (DISC). Investigators will first apply motion correction to the arterial spin labeling images using FSL-MCFLIRT and register them to the M0 image. Then, investigators will perform a pair-wise subtraction between the control and null images and apply a two-compartment model to quantify CBF. Investigators will co-register the resulting CBF map to the T1 scan followed by a transformation to MNI space. The temporal regions such as the entorhinal cortex, temporal lobe, hippocampus as well as the posterior cingulate and lateral parietal lobules will be identified using standard Harvard-Oxford Cortical and Subcortical atlas. CBF values will be compared in these regions between the 3 groups. The region of interest approach can dilute effects that are smaller than the size of the region of interest. Therefore, we will also perform permutations testing in FSL to evaluate voxel-wise CBF differences between group. In order to ensure that the voxel-wise outcomes are not mere chance, investigators will impose strict family-wise error correction for multiple comparisons.

Statistics: From these images investigators will obtain measures on global blood flow as well as regional blood flow in pre-defined regions. Investigators will utilize standard statistical models to compare the 1, 2, and 3 hour ASL to the baseline ASL to ascertain what time point produces the most robust change result. If analyses of the first few subjects necessitate, time points can shift earlier or later, depending on what time point shows the maximum change in CBF-the primary outcome.

Being tested
Lipid drink
Medical subject headings
Alzheimer Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lipid drinkDietary supplement

    100 mls of heavy cream

Study groups in NCT05218018
Study groupRoleWhat they receive
InterventionOtherOnly one arm of study
Receives: Dietary Supplement: Lipid drink

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cerebral Blood Flow Global

    Change from Baseline in Cerebral Blood Flow Global at 2 Hours

    Measured: Value at 2 hours minus value at baseline

  2. Cerebral Blood Flow Change Scores

    Change from Baseline in Cerebral Blood Flow Global at 1, 2 and 3 Hours Post Lipid Drink

    Measured: 1 hour minus baseline, 2 hours minus baseline, and 3 hours minus baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Feb 2022
  2. Study start1 Mar 2020
  3. Primary completion13 Jan 2022
  4. Study completion13 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
All participants undergo the same intervention
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05218018
Sponsor's protocol ID
STUDY00008451
Other IDs
1R01AG067563-01
Status last verified
Jan 2023
First submitted
20 Dec 2021
Last updated
8 Feb 2023
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Lipid drink in people with Alzheimer Disease, run by University of Washington at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Feb 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cerebral Blood Flow Global (time frame: Value at 2 hours minus value at baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in